Structure–activity relationships of trimethoxybenzyl piperazine N-type calcium channel inhibitors  by Pajouhesh, Hassan et al.
Bioorganic & Medicinal Chemistry Letters 22 (2012) 4153–4158Contents lists available at SciVerse ScienceDirect
Bioorganic & Medicinal Chemistry Letters
journal homepage: www.elsevier .com/ locate/bmclStructure–activity relationships of trimethoxybenzyl piperazine N-type
calcium channel inhibitors
Hassan Pajouhesh a, Zhong-Ping Feng a,b,, Lingyun Zhang a, Hossein Pajouhesh a, Xinpo Jiang a,,
Adam Hendricson a,§, Haiheng Dong a,–, Elizabeth Tringhama, Yanbing Ding a,k, Todd W. Vanderah c,
Frank Porreca c, Francesco Belardetti a, Gerald W. Zamponi b, Lester A. Mitscher d, Terrance P. Snutch e,⇑
a Zalicus Pharmaceuticals Ltd, 301-2389 Health Sciences Mall, Vancouver, BC, Canada
bDepartment of Physiology and Pharmacology, University of Calgary, Calgary, Alberta, Canada
cDepartment of Pharmacology, University of Arizona, Tucson, Arizona, USA
dDepartment of Medicinal Chemistry, University of Kansas, Lawrence, KS, USA
eMichael Smith Laboratories, University of British Columbia, Vancouver, BC, Canadaa r t i c l e i n f o
Article history:
Received 16 December 2011
Revised 9 April 2012
Accepted 10 April 2012
Available online 19 April 2012
Keywords:
N-Type calcium channel
Trimethoxybenzyl piperazine
Pain
hERG potassium channel
L-Type calcium channel0960-894X  2012 Elsevier Ltd.
http://dx.doi.org/10.1016/j.bmcl.2012.04.054
⇑ Corresponding author. Tel.: +1 604 822 6968; fax
E-mail address: snutch@msl.ubc.ca (T.P. Snutch).
 Present address: Department of Physiology and Bio
Toronto, Ontario, Canada.
 Present address: Genscript Technology Co., Ltd, 78
Xuanwu, Nanjing, Jiangsu, China.
§ Present address: Bristol-Myers Squibb, 345 Park A
– Present address: WuXi AppTec Co. Ltd, 288 Fute Zh
k Present address: Shanghai Chempartner Co. Ltd,
China.
Open access under CC Ba b s t r a c t
We previously reported the small organic N-type calcium channel blocker NP078585 that while efﬁca-
cious in animal models for pain, exhibited modest L-type calcium channel selectivity and substantial
off-target inhibition against the hERG potassium channel. Structure–activity studies to optimize
NP078585 preclinical properties resulted in compound 16, which maintained high potency for N-type
calcium channel blockade, and possessed excellent selectivity over the hERG (120-fold) and L-type
(3600-fold) channels. Compound 16 shows signiﬁcant anti-hyperalgesic activity in the spinal nerve
ligation model of neuropathic pain and is also efﬁcacious in the rat formalin model of inﬂammatory pain.
 2012 Elsevier Ltd. Open access under CC BY-NC-ND license.N N
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Figure 1. Chemical structure of NP078585.Calcium channels are the primary route of translating electrical
signals into biochemical events that underlie key processes such as
neurotransmitter release, cell excitability and gene expression.1
Calcium channels are classiﬁed into ﬁve pharmacological and
physiological subtypes: L-, N-, P/Q-, R- and T-types. Among these,
the N-, P/Q- and R-type channels have all been shown to play
key roles in neurotransmitter release.2 In particular, N-type cal-
cium channels are located at the presynaptic terminals of a subset
of spinal cord neurons where they mediate transmission of pain
signals from the periphery to the central nervous system. The block
of N-type channels with peptide agents has been shown to play a
signiﬁcant role in the pathophysiological processes of inﬂamma-
tory and neuropathic pain.3: +1 604 822 6470.
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Y-NC-ND license.Previously, we have reported NP078585 (Fig. 1) as an N-type
calcium channel blocker with good in vivo efﬁcacy in the rat for-
malin model of inﬂammatory pain following oral administration.4
NP078585 is a potent (IC50 = 0.11 lM) and CNS penetrant N-type
channel blocker with moderate selectivity over the L-type calcium
channel (IC50 = 2.8 lM). A potential development concern is that
NP078585 also blocked the hERG potassium channel
(IC50 = 0.4 lM).
In order to further optimize the development of orally available
N-type blockers, a major goal was to minimize hERG channel inhi-
bition compared to NP078585. In this regard, in the current study
we assessed; (i) modiﬁcation of aryl substituents on the benzyl
moiety bound to the piperazine core of NP078585, (ii) conversion
of amines to amides, (iii) aliphatic substitutions on the piperazine
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Figure 2. SAR studies focused on: (i) modiﬁcation of R1. R2 and R3 substituents, (ii)
changing the amine into amide, (iii) aliphatic substitution on the piperazine core,
and (iv) replacement of piperiazine core with 3-aminomethyl-pyrrolidine.
4154 H. Pajouhesh et al. / Bioorg. Med. Chem. Lett. 22 (2012) 4153–4158core, and (iv) replacement of the piperazine core with 3-amino-
methyl-pyrrolidine (Fig. 2).
Structure–activity relationship studies initially examined a
range of alternative substitution at the trimethoxybenzyl portion
of NP078585 with the aim of identifying a series with improved
in vitro channel selectivity proﬁles and with a reduction of hERG
inhibition. Compounds 1–14 were prepared from intermediates A
and B according to the general synthesis5 outlined in Scheme 1.
The structure–activity studies of this chemical series were
guided by a whole cell manual patch clamp electrophysiology as-
say for the N-type and L-type calcium channel with further assess-
ment for hERG activity.6 The replacement of R1 and R3 groups on
the benzyl region of parent compound NP078585 with a t-butyl
group (Table 1), in general resulted in maintaining good N-type
channel blocking afﬁnity for most compounds. This region of the
molecule appears to be fairly accommodating, accepting a t-butyl
group in 3 and 5 positions being the most optimal substituents,
such as compounds 3–12, all of which showed better or similarN N
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Scheme 1. Reagents and conditions: (a) (i) TFA, CH2Cl2, (ii) benzoic acid analogs, EDC, D
analogs, EDC, DMAP, CH2Cl2; (d) (i) benzoic acid analogs, EDC, DMAP,CH2Cl2, (ii) LiAlH4. TN-type afﬁnities compared to the parent compound NP078585.
The 3,5-di-t-butyl analogs (compounds 11–12) also maintained
high afﬁnity N-type inhibition with IC50 values of 0.14–0.3 lM.
Compared to NP078585, the addition of a 4-methoxy substituent
(compound 10) slightly improved afﬁnity (0.09 lM) and addi-
tionally dramatically improved selectivity both over the L-type
channel to greater than 900-fold (IC50 81 lM, not shown) and
the hERG channel by approximately 100-fold (IC50 9 lM). From
this initial series, we determined that 3,5-substitution of the phe-
nyl ring was preferred. Further, the incorporation of a hydrogen
bond acceptor (–OCH3) as in the case of compound 10 increased
the selectivity for the N-type over the L-type and hERG targets.
In general, the amine-linked analogues exhibited higher afﬁnity
for hERG as compared to the amide counterparts.
Using aryl substituents (R1 = t-butyl, R2 = OCH3, R3 = t-butyl)
and an amide-linked functional group, we further explored substi-
tutions off the piperazine ring with aliphatic groups. Table 2 shows
that S-Me substitution was tolerated off the piperazine ring adja-
cent to the linker (compound 15) although resulted in high afﬁnity
hERG channel blockade (IC50 0.9 lM). Contrastingly, S-Me substi-
tution adjacent to the benzoyl linker (compound 16) resulted in
excellent N-type channel blockade and approximately 3600-fold
selectivity over the L-type channel. In addition, compound 16
maintained the favorable hERG channel block of the parent com-
pound 10 (IC50 = 4.9 lM). Due to its combined N-type afﬁnity
and excellent selectivity proﬁle compound 16 was progressed into
in vivo anti-nociception assessment.
Further optimization of NP078585 was attempted by replace-
ment of the piperazine core with 3-aminomethyl-pyrrolidine. We
hypothesized that 3-aminomethyl-pyrrolidine could be a potential
bioisostere for the piperazine core due to the relatively planar con-
formation of the pyrrolidine ring in combination with the ﬂexible
3-aminomethyl group. To test this, we synthesized a series of com-
pounds containing amine and amide groups, in combination with aF
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MAP, CH2Cl2; (b) LiAlH4. THF; (c) (i) LiAlH4. THF, (ii) TFA, CH2Cl2, (iii) benzoic acid
HF; (e) (i) TFA, CH2Cl2, (ii) 6,6-bis(4-ﬂuorophenyl)hexanoic acid, EDC, DMAP, CH2Cl2.
Table 1
Blocking activities of compounds 1–14 against the N-type calcium channel and the hERG potassium channel
N N
R1
R2
R3
F
F
y
X
Compound R1 R2 R3 X Y N-type Est. IC50 (lM) hERG Est. IC50 (lM)
NP078585 OCH3 OCH3 OCH3 H H 0.11 (±0.03) 0.4
1 OCH3 OH OCH3 H H 0.4 (±0.2) ND
2 OCH3 OH OCH3 O O 0.6 (±0.39) ND
3 t-Butyl OH t-Butyl H H 0.04 (±0.03) 0.1
4 t-Butyl OH t-Butyl O H 0.15 (±0.08) 0.25
5 t-Butyl OH t-Butyl H O 0.18 (±0.12) ND
6 t-Butyl OH t-Butyl O O 0.22 (±0.11) ND
7 t-Butyl OCH3 t-Butyl H H 0.09 (0.04) 0.1
8 t-Butyl OCH3 t-Butyl O H 0.11 (±0.02) 0.66
9 t-Butyl OCH3 t-Butyl H O 0.1 (±0.03) 0.13
10 t-Butyl OCH3 t-Butyl O O 0.09 (±0.05) 9.0
11 t-Butyl H t-Butyl H H 0.14 (±0.08) 0.1
12 t-Butyl H t-Butyl O O 0.3 (±0.25) ND
13 CF3 H CF3 H H 1.1 (±1) ND
14 CF3 H CF3 O O 0.51(±0.28) ND
Table 2
Blocking activities of compounds 15–16
Compound Structure N-type Est. IC50 (lM) L-type Est. IC50 (lM) hERG Est. IC50 (lM)
15
N N
O
F
F
O
O
0.01 (n = 2) ND 0.9
16
N N
O
F
F
OO
0.04 (±0.03) 144 4.9
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elements of NP078585 and compound 10.
Initial efforts in this study focused on analogs wherein substitu-
tions on the aryl group were varied (Table 3). The synthesis of
these compounds is as described in Scheme 2 and is illustrative
of the general procedure. Brieﬂy, readily available 1-benzyl-pyrr-
olidin-3-ylmethyl- carbamic acid tert-butyl ester was debenzylat-
ed via catalytic hydrogenation followed by coupling with
6,6-bis(4-ﬂuorophenyl)hexanoic acid mediated by EDC and DMAP
to provide the desired intermediate. Subsequent deprotection of
the Boc group and reaction with the appropriate benzoic acid pro-
vided desired compounds. Reduction of the di-amide moiety with
LiAlH4 proceeded smoothly to afford di-amines compounds.7
Compounds (17–28) generally exhibited highly favorable N-
type channel inhibition (IC50 values 0.04–0.9 lM). Of these, com-
pounds 18–19 and 26–27 containing bulky substituents (t-butyl)
on the 3,5-position of the aryl group showed improved N-type
channel inhibition compared to NP078585. Of note, compound 19
with the highest N-type afﬁnity also showed excellent selectivity
over the L-type calcium channel (750-fold; not shown). Extending
the substitution of the phenyl ring to triﬂuoromethyl (compounds20–21) did not improve activity concerning N-type blockade and
further, the best of these (compound 20, IC50 0.2 lM) exhibited
a poor hERG proﬁle. Comparing amine-linked compounds 23–27
to their amide counterparts (compounds 17–21), in general the
di-amine linked analogues possessed higher afﬁnity for both the
N-type calcium channel and the hERG potassium channel as com-
pared to their di-amide counterparts.
The stereogenic center introduced by the pyrrolidine ring ap-
peared to have little effect on N-type calcium channel activity with
the R:S IC50 values approaching unity (Table 4). These observations
would seem to be one of the many exceptions to Pfeiffer’s rule,
which states that the higher the activity of a eutomer, the higher
the separation in activities between eutomer and distomer.8
We further then focused on understanding the effect of replac-
ing one phenyl group on the benzhydryl with piperidine (Scheme
3). The introduction of the N-piperidinyl moiety (compounds 35–
37) resulted in analogs with reduced N-type afﬁnity relative to
the corresponding phenyl analogs (see Table 5).
Based on the encouraging results associated with compound 19,
we investigated whether swapping the ‘left hand’ and ‘right hand’
side moieties attached to the 3-amino(methyl) pyrrolidine core
Table 3
Blocking activities of compounds 17–27 against the N-type calcium channel and the hERG potassium channel
NNH
F
F
R1
YX
R2
R3
Compound R1 R2 R3 X Y N-type Est. IC50 (lM) hERG Est. IC50 (lM)
17 H t-Butyl H O O 0.08 (±0.04) 0.82
18 t-Butyl H t-Butyl O O 0.11 (±0.06) 2.8
19 t-Butyl OCH3 t-Butyl O O 0.04 (n = 2) 1.9
20 CF3 H CF3 O O 0.21 (±0.15) 0.7
21 CF3 H F O O 0.75 (±1.24) ND
22 t-Butyl OCH3 t-Butyl O H 0.09 (n = 2) 0.1
23 OCH3 OCH3 OCH3 O H 0.28 (±0.18) 0.1
24 CF3 H CF3 O H 0.15 (n = 2) 0.1
25 OCH3 OCH3 OCH3 H H 0.06 (±0.04) 0.04
26 t-Butyl OH t-Butyl H H 0.05 (±0.03) 0.87
27 t-Butyl H t-Butyl H H 0.03 (n = 2) 0.46
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Scheme 2. Reagents and conditions: (a) Pd/C, H2, MeOH; (b) 6,6-bis(4-ﬂuorophenyl)hexanoic acid or 6-(1-methylpiperidin-4-yl)-6-phenylhexanoic acid, EDC, DMAP, CH2Cl2;
(c) (i) TFA, CH2Cl2, (ii) benzoic acid analogs, EDC, DMAP, CH2Cl2; (d) LiAlH4THF; (e) (i) LiAlH4THF, (ii) TFA, CH2Cl2, (iii) benzoic acid analogs, EDC, DMAP, CH2Cl2.
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analogue with excellent afﬁnity for N-type calcium channel (com-
pound 39, IC50 0.01 lM). Unfortunately, these modiﬁcations did
not offer any advantages concerning hERG selectivity over com-
pound 20.
Of the compounds synthesized and evaluated, compounds 10
and 16 exhibited the most promising overall in vitro target pro-
ﬁles; N-type blocking IC50s 0.04–0.09 uM and excellent selectiv-
ity over both the L-type calcium channel (900- to 3600-fold)
and hERG potassium channel ( 100- to 122-fold). Reﬂective of
these combined properties, compounds 10 and 16 were selected
for in vivo assessment in the rat formalin model of inﬂammatory
pain.9 Upon intraperitoneal (ip) administration only compound16 exhibited signiﬁcant antinociceptive activity (50–60% of
vehicle-treated group) in phase II and phase IIA of the formalin
response (Table 7).
Compounds 10 and 16 were also evaluated for activity in the
Chung model of neuropathic pain10 with two behavioral endpoints
used: mechanical allodynia11 and thermal hyperalgesia.12 Animals
were administered a single 30 mg/kg oral dose of each compound
and were tested at 30 min intervals during a 2–3 h test period
beginning 30 min after test compound administration. One-way
ANOVA followed by the Bonferroni test were employed on the ori-
ginal raw data (not normalized) to establish the statistical signiﬁ-
cance of the differences observed with the post SNL-baseline
value. Compounds 10 and 16 both demonstrated efﬁcacious
Table 4
The effect of chirality for compounds 28–33 on the N-type and hERG blocking activities
NN
H
F
F
R1
OO
R2
R3
Compound Stereochemistry R1 R2 R3 N-type Est. IC50 (lM) hERG Est. IC50 (lM)
28 R t-Butyl H t-Butyl 0.16 (±0.18) 5.0
29 S t-Butyl H t-Butyl 0.12 (±0.03) 2.0
30 R t-Butyl OCH3 t-Butyl 0.15 (±0.02) 5.0
31 S t-Butyl OCH3 t-Butyl 0.36 (±0.2) 2.0
32 R CF3 H CF3 0.1 (±0.02) 0.75
33 S CF3 H CF3 0.09 (±0.03) 0.8
Table 6
N-type calcium channel and hERG potassium channel blocking activities for compounds 3
N
H
F
F
X
Compound R1 R2 R3 X
38 OCH3 OCH3 OCH3 O
39 t-Butyl OCH3 t-Butyl O
40 OCH3 OCH3 OCH3 H
41 t-Butyl OH t-Butyl H
42 t-Butyl OCH3 t-Butyl H
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Scheme 3. Reagents and conditions: (a) NaOMe, MeOH; (b) Dibal, CH2Cl2; (c)
LiHMDS, THF; (d) Pd/C, H2, 50 Psi, MeOH.
Table 5
N-type calcium channel blocking activities for compounds 34–37
NN
H
R1
OO
R2
R3
N
Compound R1 R2 R3 N-type Est. IC50 (lM)
34 OCH3 OCH3 OCH3 3.2 (±2.8)
35 Isopropyl OCH3 Isopropyl 1.9 (±2.2)
36 CH3 OCH3 CH3 0.1 (±0.02)
37 Cl H Cl 0.88 (±0.33)
Table 7
Efﬁcacy of compounds 10 and 16 in the rat formalin model of acute inﬂammatory
pain
Compound % Of vehicle response
Phase I Phase II Phase IIA
10 79 ± 6 80 ± 7 67 ± 5
16 79 ± 9 61 ± 9⁄⁄⁄ 50 ± 12⁄⁄
Compounds, prepared in propylene glycol, were administered at a dose of 30 mg/kg
ip at 3 mL/kg 30 min prior to intraplantar injection of formalin into the hindpaw.
Data are the mean percent of vehicle effect (MPE) ± SEM, n = 5 animals tested for
compound 10 and n = 6 animals for compound 16. Data were analyzed for signiﬁ-
cance using a one-way ANOVA to vehicle-treated group. ⁄⁄P <0.01; ⁄⁄⁄P <0.001
H. Pajouhesh et al. / Bioorg. Med. Chem. Lett. 22 (2012) 4153–4158 4157inhibition of nerve ligation-induced thermal hyperalgesia (ranging
from 54% to 86% maximal antinociception; Table 8). Contrasting-
ly, only compound 16 exhibited discernible antiallodynic effects in
vivo. This may reﬂect distinct underlying pathophysiological
mechanisms contributing to these two pain behavioral endpoints
together with any as yet-to-be determined unique state-dependent
target and/or off-target activities related to compounds 10 and 16.
In summary, we have described a series of piperazine and 3-
amino(methyl)pyrrrolidine analogues, some of which display both
excellent potency as N-type calcium channel antagonists and pos-
sess favorable selectivity over the hERG potassium channel. Among
these, compound 16 exhibited good selectivity over the L-type cal-
cium channel and showed analgesic activity in both inﬂammatory
and neuropathic rat pain models. The development of N-type
calcium channel blockers for eventual clinical usage will require
optimization of multiple parameters, including high afﬁnity and
selectivity for the N-type target, suitable pharmacokinetic charac-8–42
N
Y
R3
R2
R1
Y N-type Est. IC50 (lM) hERG Est. IC50 (lM)
O 0.84 (±0.39) 0.75
O 1.9 (±2.2) 0.65
H 0.06 (±0.06) 0.1
H 0.004 (n = 2) 0.01
H 0.032 0.11
Table 8
Efﬁcacy in the neuropathic SNL rat model for compounds 10 and 16
Compound Tactile allodynia: maximum % antinociception at 60 min Thermal hyperalgesia: maximum % antinociception at 60 min
10 1.9 ± 1.4 54.2 ± 12.9⁄⁄
16 31.7 ± 6.9⁄⁄ 85.8 ± 14.1⁄⁄
Compounds, prepared in propylene glycol, were administered at a dose of 30 mg/kg po at 1 mL/kg after baseline assessment for neuropathic pain and behavioral assessments
were performed at 30 min intervals post-administration, up to 3 h. Data are the mean percent of maximal possible antinociception ± SEM; n = 5–6 animals. The following
formula was used to calculate the % anti-allodynic activity: 100%  [(paw withdrawal thresholds after drug treatment  postSNL baseline paw withdrawal thresholds)/
(preSNL baseline paw withdrawal thresholds  postSNL baseline paw withdrawal thresholds). The following formula was used to calculate the % anti-hyperalgesic activity:
100%  [(paw withdrawal latencies after drug treatment  postSNL baseline paw withdrawal latencies)/(preSNL baseline paw withdrawal latencies  postSNL baseline paw
withdrawal latencies). Data from the ipsilateral paw were also assessed by a one-way ANOVA-post-hoc for statistical signiﬁcance. ⁄⁄P <0.01.
4158 H. Pajouhesh et al. / Bioorg. Med. Chem. Lett. 22 (2012) 4153–4158teristics incorporating oral bioavailability and blood–brain barrier
penetration, and a wide therapeutic index against the cardiovascu-
lar, nervous and other systems. Similar to our previous reports,4,13
only a subset of high afﬁnity in vitro N-type channel blockers in the
current study exhibited efﬁcacy in rodent neuropathic and inﬂam-
matory pain models. An exact correlation between in vitro target
afﬁnity and in vivo analgesia is generally lacking across many sim-
ilar studies, making direct compound-based predictive assess-
ments difﬁcult and requiring empirical elucidation of efﬁcacy. In
part, this may reﬂect a requirement for an optimal combination
of high afﬁnity N-type channel blockade acting via a state- and/
or frequency-dependence mechanism and reﬂective of the under-
lying pathophysiology associated with speciﬁc pain states.14
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